Johnson & Johnson (JNJ)
| Market Cap | 353.45B |
| Revenue (ttm) | 81.80B |
| Net Income (ttm) | 38.48B |
| Shares Out | 2.41B |
| EPS (ttm) | 15.09 |
| PE Ratio | 9.72 |
| Forward PE | 13.59 |
| Dividend | $4.96 (3.38%) |
| Ex-Dividend Date | May 20, 2024 |
| Volume | 12,586,776 |
| Open | 145.57 |
| Previous Close | 145.28 |
| Day's Range | 145.19 - 147.48 |
| 52-Week Range | 143.13 - 175.97 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 166.21 (+13.32%) |
| Earnings Date | Jul 18, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, JNJ's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $166.21, which is an increase of 13.32% from the latest price.
News
Johnson & Johnson Completes Acquisition of Shockwave Medical
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate a...
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Calls Of The Day: Eli Lilly, UnitedHealth Group, Abbott Labs and Johnson & Johnson
The Investment Committee discuss the latest Calls of the Day.
Sarepta Therapeutics Set to Join S&P MidCap 400
NEW YORK , May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monda...
J&J's treatment for depression succeeds in late stage study
Johnson & Johnson said on Wednesday its experimental therapy, seltorexant, met all main and secondary goals in a late-stage study evaluating it in patients with major depressive disorder (MDD) and ins...
Trade Tracker: Stephanie Link sells Johnson & Johnson
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to break down her latest trades.
J&J acquires rights to skin disorder drug for $1.25 bln
Johnson & Johnson said on Tuesday it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion.
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing...
Cancer victims file class action against Johnson & Johnson over ‘fraudulent' bankruptcies
A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to r...
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies
A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve...
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation
TRENTON, N.J.--(BUSINESS WIRE)--Women who previously filed lawsuits against Johnson & Johnson for damages caused by its defective talc products have filed a class action lawsuit in U.S. District Court...
J&J-backed startup Rapport files for US IPO
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
Ex-Dividend Reminder: Nuvei, Walgreens And Johnson & Johnson
On 5/20/24, Nuvei, Walgreens Boots Alliance, and Johnson & Johnson will all trade ex-dividend for their respective upcoming dividends. Nuvei will pay its quarterly dividend of $0.10 on 6/6/24, Walgree...
Johnson & Johnson to acquire Proteologix for $850 million
Johnson & Johnson on Thursday said it would acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment.
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company...
Is Johnson & Johnson Stock A Better Pick Over Merck?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck (NYSE: MRK). Although Merck trades at a higher valuation of 5.5x trailing re...
J&J's $13 billion bid for Shockwave turns to Wall Street for funding
Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dul...
J&J to exit Kenvue, a year after spinoff
Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health bus...
Kenvue Announces Launch of Secondary Offering
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.
SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medica...
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hot...
Pharma giant adds Israel to list of Middle East markets after omission raises questions
Johnson & Johnson has added Israel to its Customer Connect order management website after questions rose over why it was excluded while "Palestine" was not.
Johnson & Johnson proposes to pay $6.5B to settle talc ovarian cancer lawsuits in US
Through a bankruptcy filing of its subsidiary company, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S.
Johnson & Johnson Proposes Nearly $6.5B Package to Settle Talc Ovarian Cancer Suits
Johnson & Johnson (JNJ) shares rose in early trading Wednesday after the company announced a plan that would resolve nearly all pending litigation over claims that its talc powder caused ovarian cance...